BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Hairy cell leukemia (HCL) shows unique clinicopathological and biological features. HCL responds well to purine analogs but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukem...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Pettirossi, Valentina, Santi, Alessia, Imperi, Elisa, Russo, Guido, Pucciarini, Alessandra, Bigerna, Barbara, Schiavoni, Gianluca, Fortini, Elisabetta, Spanhol-Rosseto, Ariele, Sportoletti, Paolo, Mannucci, Roberta, Martelli, Maria Paola, Klein-Hitpass, Ludger, Falini, Brunangelo, Tiacci, Enrico
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2015
Onderwerpen:
Plenary Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4366655/
https://ncbi.nlm.nih.gov/pubmed/25480661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-603100
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items